<code id='51417D1440'></code><style id='51417D1440'></style>
    • <acronym id='51417D1440'></acronym>
      <center id='51417D1440'><center id='51417D1440'><tfoot id='51417D1440'></tfoot></center><abbr id='51417D1440'><dir id='51417D1440'><tfoot id='51417D1440'></tfoot><noframes id='51417D1440'>

    • <optgroup id='51417D1440'><strike id='51417D1440'><sup id='51417D1440'></sup></strike><code id='51417D1440'></code></optgroup>
        1. <b id='51417D1440'><label id='51417D1440'><select id='51417D1440'><dt id='51417D1440'><span id='51417D1440'></span></dt></select></label></b><u id='51417D1440'></u>
          <i id='51417D1440'><strike id='51417D1440'><tt id='51417D1440'><pre id='51417D1440'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive